Steven B. Binion
Plus aucun poste en cours
Profil
Steven B.
Binion is Vice President of Regulatory Affairs and Quality Assurance for NeoPharm, Inc., which he joined in December 2004.
Previously, he spent over 10 years at Baxter International as Vice President of Regulatory Affairs for the Transfusion Therapies Division.
Prior to joining Baxter, Dr. Binion served as Director of Worldwide Regulatory Affairs for the BOTOX Program of Allergan Pharmaceuticals, Inc. He received a Bachelor's degree in Microbiology from the University of Florida, an MBA from the University of St. Thomas in Minnesota and a PhD in Immunology from Kansas State University.
Anciens postes connus de Steven B. Binion
| Sociétés | Poste | Fin |
|---|---|---|
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Conseiller Juridique Général | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
